AnaCardio receives IND approval from the FDA for AC01 to Start a Clinical Pharmacology Study
Stockholm, Sweden, August 17, 2023 AnaCardio, a Swedish clinical-stage biopharmaceutical company focussing on developing novel contractile agents to treat patients with heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted the company’s Investigational New Drug (IND) application for the investigational drug AC01. The approval enables expansion of the clinical development […]
AnaCardio reports first patient dosed in the GOAL-HF1 study, a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK
Solna, Sweden and Lugano, Switzerland, April 13, 2022 AnaCardio, a Swedish clinical-stage biopharmaceutical company focussed on developing novel contractile agents with a unique mode of-action based on the ghrelin signaling pathway, today announced that the first patient has been successfully dosed in its GOAL-HF1 study of AC01 in patients with heart failure and reduced ejection […]
Ghrelin treatment in heart failure patients showed increased contractility of the heart
Stockholm, Sweden, March 14 , 2023 AnaCardio´s founder Prof Lars Lund and colleagues from The Karolinska Institutet publish study on ghrelin treatment in patients with heart failure and in isolated heart cells, demonstrating increased contractility and a novel mechanism of action AnaCardio, a Swedish clinical-stage biopharmaceutical company focused on developing novel contractile agents with a […]
AnaCardio Receives Regulatory Approval to Start a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK
Stockholm, Sweden, November 17, 2022 AnaCardio today announces approval for the GOAL-HF1 Phase 1b/2a study from the competent authorities and ethics committes in Sweden, The Netherlands, Italy and the United Kingdom. This 28-day study will evaluate the effects of orally administered AC01 on safety, tolerability, pharmacokinetics and a series of pharmacodynamic readouts in patients with […]
AnaCardio raises SEK 150 million to advance drug candidate AC01 in heart failure
Stockholm, Sweden, September 7, 2022 AnaCardio raises SEK 150 million to advance drug candidate AC01 in heart failureAnaCardio announced today the completion of a SEK 150 M Series A financing round, co-led by Flerie Invest AB (Flerie) and Industrifonden. 3B Future Health Fund (3BFHF) joined Flerie and Industrifonden to complete the round together with the […]
AnaCardio exercises option to license a program in heart failure from Helsinn
Lugano, Switzerland and Stockholm, Sweden, February 3, 2022 Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, are pleased to announce that AnaCardio has exercised its option […]
AnaCardio raises SEK 33 million for development of a novel therapy for heart failure
Stockholm, Sweden, 3 February 2022 AnaCardio raises SEK 33 million for development of a novel therapy for heart failureAnaCardio today announced the completion of a fundrasing round of 33 MSEK. The funds will be used to progress clinical development of its lead asset in heart failure. The capital injection is comprised of a convertible loan […]
AnaCardio strengthens its organization
Stockholm Sweden – October 25, 2021 Karolinska Development’s portfolio company AnaCardio strengthens its organization to facilitate clinical trial of the drug candidate AC01 in heart failure. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company AnaCardio has strengthened its organization in preparation for the initiation of a phase 1b/2a study of its […]
AnaCardio appoints Patrik Strömberg as CEO
Stockholm, Sweden, 22 October 2021 AnaCardio appoints Patrik Strömberg as CEO.AnaCardio AB announces today that Patrik Strömberg has been appointed Chief Executive Officer effective as of September 1, 2021. Patrik Strömberg joins AnaCardio from his previous role as Vice President, External Innovation, Sourcing & Evaluation at Swedish Orphan Biovitrum AB (Sobi). Patrik has extensive experience […]
Karolinska Development expands its portfolio through new investment in AnaCardio
Stockholm, Sweden – June 17, 2021 Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the company has acquired approximately 21 percent of the shares in AnaCardio AB. The new portfolio company develops drugs for the treatment of heart failure, based on groundbreaking research from Karolinska Institutet. The company’s most advanced project is deemed to […]